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Pulmonary hypertension (PH) is a fatal disease and public health concern.1 The global prevalence of PH is 
not known1 and a major focus is to establish registries in order to determine the actual prevalence of PH per 
country2. PH prevalence is largely subject to aetiology, geographical region and the tools used to make a diagnosis 
(e.g. echocardiography or right heart catheterisation).1 In Africa, the prevalence of PH that is secondary to HIV differs 
from its prevalence that is secondary to rheumatic heart disease or schistosomiasis. For example, PH prevalence 
in HIV is approximately 14%3, while the prevalence can be 1% or 10% in schistosomiasis4. In comparison with 
a world population of some eight billion people, the relatively ‘low’ number of people who have been diagnosed 
with or who have succumbed to PH has triggered the assumption that it is a rare disease, which is how it is also 
reported throughout the literature.
However, let us consider the following. In one study of 277 people living with HIV, 18 were diagnosed with PH.5 In a 
recent systematic review and meta-analysis of studies with 42 642 people living with HIV from 17 countries, the 
overall PH prevalence was 8.3% in adults – a total of about 3 540 people with PH.3 Surely this is not ‘rare’ disease if 
one considers that this is ultimately the number of people who might die due to PH? To add an interesting dimension, 
during the 2019 festive season in South Africa, approximately 600 people died in motor accidents (based on public 
reports of the National Minister of Transport). The count of these deaths is always met with shock, sadness, and 
calls for urgent action for prevention – and rightly so. However, that fewer deaths are reported for car accidents 
compared to other causes (e.g. infectious diseases that kill millions of people), does not make the one ‘rare’ and 
the other not. More importantly, simply because fewer people have died from one disease than from another, does 
not make that one disease less important. PH causes morbidity and mortality, period, and should be considered a 
formidable health threat.
PH is a clinical complication of many diseases that are highly prevalent in South Africa. Altogether, millions of 
South Africans suffer from heart disease, tuberculosis, HIV and schistosomiasis.6 Thus, many people who currently 
have these diseases may later develop and succumb to PH, especially considering that the symptoms of PH are 
often misperceived, and patients may remain undiagnosed or are diagnosed too late. This may be considered an 
oversimplification or romanticised exaggeration of a poorly understood reality. However, the matter should be settled: 
PH is not a ‘rare’ disease7 because it has already cost many lives and, from a patient’s perspective, the identification 
of a disease as ‘rare’ is irrelevant, because their own clinical reality takes precedence8. From a philosophical 
viewpoint, I believe that we should challenge the persistent portrayal of PH as ‘rare’.
Suggesting that PH is a rare disease has negative consequences for PH research and public health efforts. The use 
of the term ‘rare’ may create several negative impressions in the PH research/clinical sector, two of which I 
highlight here. First, describing PH as a ‘rare’ disease may create the impression that more research funding should 
not be funnelled towards PH research. Second, it can create the erroneous impression that it is not necessary to 
make targeted therapy available and affordable to all patients (those with and without medical aid insurance, and 
those in developing countries). As the clinical and research community, and other stakeholders, we should begin 
to consider that PH might become a greater health concern in South Africa, given the high prevalence of diseases 
or risk factors, like heart disease, tuberculosis, HIV and schistosomiasis. It is perhaps time that we reflect on this 
matter with due diligence and we ask ourselves this important philosophical question: What is rare?
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